Access Portal
Visit Operon Insights Platform
Access your research library, financial models, and Signal Weekly reports on the dedicated Insights platform.
Go to Insights Portal →
insights.operonresearch.com
Deep-dive industry reports, proprietary financial models, and a weekly data-driven research report — all built on a stack of trackers Operon maintains continuously. For institutional investors and corporate decision-makers covering the sector.
Access your research library, financial models, and Signal Weekly reports on the dedicated Insights platform.
A weekly research report tracking the proprietary datasets that drive Operon's view of the industry — NIH funding flows, clinical trials activity, life sciences hiring, web traffic, and other public and licensed sources.
The Signal is detailed, timely, and decisive. It's the recurring deliverable subscribers can build their week around — and it's where the trackers behind every other Operon report come together in one place.
The library houses Operon's full body of published research. Subscribers receive new research on a regular cadence as it's published — never delayed, never tier-restricted within the library access they hold.
What's inside:
Every report is built on Operon's underlying data layer and is grounded in the trackers we maintain — not on narrative or consensus.
Operon Sessions provides subscribers with access to curated content from C-Suite executives and Key Opinion Leaders, focused on thematic topics shaping the future of the industry. This includes Operon-led discussions on market research and competitive intelligence.
Tailored multimedia content — exclusive recordings and deep-dives produced by Operon researchers.
Operon publishes two classes of financial models, available to subscribers at the appropriate access tiers.
Company-level models Access — full income statement, segment-level revenue build, margin walk, and forward forecasts for each name in our coverage. Models are updated as new data lands — earnings, guidance updates, end-market trackers, and industry events.
Market-level models Elite — top-down market sizing and share models for the end markets and product categories we cover. Used by clients for diligence, scenario planning, and competitive intelligence.
Operon's research is built on a continuously maintained stack of public and licensed datasets. Each tracker is designed to read against a specific industry question, and each report and model is grounded in this data layer before any analysis is written.
Tracking federal research funding flows by institution, study section, and award category. A leading indicator of life sciences research activity and downstream tools and diagnostics demand.
Trial starts, enrollment patterns, and sponsor activity across therapeutic areas. Reads against bioprocessing capacity, CRO demand, and downstream lab activity.
Job postings data across life sciences companies and research institutions. A real-time signal on company-level investment and end-market demand.
Traffic patterns for companies and platforms across the sector. Useful for early reads on product launches, tool adoption, and competitive share shift.
Plus public filings, public statements, and licensed third-party data providers.
Instruments, consumables, and reagents across bioprocessing, NGS, mass spec, microscopy, and the broader bench.
Single-use and stainless infrastructure, cell culture media, fill-finish, and bioreactor capacity dynamics.
Platforms, consumables, and applications across clinical, research, and emerging segments.
Core lab automation, molecular diagnostics, point-of-care, and the regulatory landscape shaping LDT.
Reference labs, hospital outreach, and the structural dynamics of the testing market.
CROs, biomanufacturing capacity, and the contract services value chain.
We don't rate stocks or set price targets. Our focus is what drives industry growth and competitive share shift — the fundamentals that matter for long-term investors.
Most sell-side coverage is shaped by what the Street already believes. Operon writes against that — focused on the trends and structural shifts that move industry growth, not on echoing the prevailing view.
Operon does not publish to consensus. When our forecasts differ from Street estimates and our trackers support the divergence, we publish them — that's where subscribers find the most value.